Lucid Capital Markets Starts Relmada Therapeutics Inc (RLMD) at Buy Mar 2, 2026 06:05AM
Leerink Partners Upgrades Relmada Therapeutics Inc (RLMD) to Outperform Jan 23, 2026 06:20AM
Relmada gets FDA alignment on NDV-01 bladder cancer trial designs Jan 12, 2026 07:02AM
Why Jefferies sees these stocks as standout biotech plays in 2026 Dec 23, 2025 10:00AM
Jefferies Starts Relmada Therapeutics Inc (RLMD) at Buy Dec 22, 2025 12:49AM


Dec 21, 2025 08:00PM Here's the list of top biotech stocks to own for 2026
Nov 19, 2025 04:02AM Mizuho Upgrades Relmada Therapeutics Inc (RLMD) to Outperform
Nov 13, 2025 04:31PM Relmada Therapeutics (RLMD) Tops Q3 EPS by 15c
Sep 16, 2025 11:20AM Sidoti Events, LLC's Virtual September Small-Cap Conference
Sep 16, 2025 11:20AM Sidoti Events, LLC's Virtual September Small-Cap Conference
Sep 16, 2025 11:20AM Sidoti Events, LLC's Virtual September Small-Cap Conference
Sep 16, 2025 11:20AM Sidoti Events, LLC's Virtual September Small-Cap Conference
Sep 10, 2025 07:15AM Relmada outlines Phase 3 trial plans for bladder cancer drug NDV-01
Aug 7, 2025 04:22PM Relmada Therapeutics (RLMD) Tops Q2 EPS by 10c
Jul 15, 2025 08:02AM Relmada Therapeutics names Yair Lotan to chair clinical advisory board
May 12, 2025 04:04PM Relmada Therapeutics (RLMD) Misses Q1 EPS by 21c
Apr 28, 2025 01:39PM Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data
Mar 26, 2025 05:59AM Mizuho Reiterates Neutral Rating on Relmada Therapeutics Inc (RLMD)
Mar 25, 2025 07:32AM Relmada Therapeutics (RLMD) Licenses NDV-01 from Trigone Pharma
Feb 6, 2025 03:18PM Relmada Therapeutics Inc (RLMD) Sepranolone deal could Have 'blockbuster potential' - Mizuho
Feb 6, 2025 07:30AM Relmada Therapeutics (RLMD) Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
Dec 9, 2024 07:31AM Relmada Therapeutics (RLMD) to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Dec 5, 2024 02:59AM Mizuho Downgrades Relmada Therapeutics Inc (RLMD) to Neutral
Dec 4, 2024 12:15PM Leerink Partners Downgrades Relmada Therapeutics Inc (RLMD) to Market Perform
Dec 4, 2024 07:30AM Relmada Therapeutics (RLMD) Reports That Data Monitoring Committee Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficac
Nov 14, 2024 07:31AM Relmada Therapeutics (RLMD) Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
Nov 7, 2024 04:34PM Relmada Therapeutics (RLMD) Misses Q3 EPS by 4c
Sep 17, 2024 04:01AM Jefferies Upgrades Relmada Therapeutics Inc (RLMD) to Buy
Sep 12, 2024 07:54AM Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD)
Aug 30, 2024 04:25PM Relmada Therapeutics (RLMD) Files $250M Mixed Shelf
Aug 7, 2024 04:22PM Relmada Therapeutics (RLMD) Tops Q2 EPS by 24c
Jun 18, 2024 08:31AM Relmada Therapeutics (RLMD) Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017